FI70704C - Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet - Google Patents

Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet Download PDF

Info

Publication number
FI70704C
FI70704C FI791034A FI791034A FI70704C FI 70704 C FI70704 C FI 70704C FI 791034 A FI791034 A FI 791034A FI 791034 A FI791034 A FI 791034A FI 70704 C FI70704 C FI 70704C
Authority
FI
Finland
Prior art keywords
propoxy
dihydrocarbostyril
group
compound
crystals
Prior art date
Application number
FI791034A
Other languages
English (en)
Finnish (fi)
Other versions
FI70704B (fi
FI791034A7 (fi
Inventor
Kazuo Banno
Takafumi Fujioka
Yasuo Oshiro
Kazuyuki Nakagawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of FI791034A7 publication Critical patent/FI791034A7/fi
Publication of FI70704B publication Critical patent/FI70704B/fi
Application granted granted Critical
Publication of FI70704C publication Critical patent/FI70704C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI791034A 1978-03-30 1979-03-28 Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet FI70704C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3778378A JPS54130587A (en) 1978-03-30 1978-03-30 Carbostyryl derivative
JP3778378 1978-03-30

Publications (3)

Publication Number Publication Date
FI791034A7 FI791034A7 (fi) 1979-10-01
FI70704B FI70704B (fi) 1986-06-26
FI70704C true FI70704C (fi) 1986-10-06

Family

ID=12507080

Family Applications (1)

Application Number Title Priority Date Filing Date
FI791034A FI70704C (fi) 1978-03-30 1979-03-28 Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet

Country Status (21)

Country Link
US (2) US4734416A (fr)
JP (1) JPS54130587A (fr)
AT (1) AT376432B (fr)
AU (1) AU515531B2 (fr)
BE (1) BE875174A (fr)
CA (1) CA1117110A (fr)
CH (2) CH641455A5 (fr)
DE (2) DE2912105C2 (fr)
DK (1) DK158225C (fr)
ES (4) ES479134A1 (fr)
FI (1) FI70704C (fr)
FR (1) FR2421174A1 (fr)
GB (1) GB2017701B (fr)
IT (1) IT1119284B (fr)
MX (1) MX5862E (fr)
NL (1) NL183189C (fr)
NO (1) NO151321C (fr)
PT (1) PT69422A (fr)
SE (1) SE434945B (fr)
SU (2) SU1140687A3 (fr)
ZA (1) ZA791516B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
DE3034237A1 (de) * 1979-09-18 1981-04-16 Otsuka Pharmaceutical Co. Ltd., Tokyo Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS57193461A (en) * 1981-05-22 1982-11-27 Otsuka Pharmaceut Co Ltd Benzazepine derivative
DE3442570A1 (de) * 1984-11-22 1986-05-22 Hoechst Ag, 6230 Frankfurt Neue substituierte phenylpiperazinderivate, verfahren zu deren herstellung und die verwendung substituierter phenylpiperazinderivate als aggressionshemmer fuer tiere
JPS6129331A (ja) * 1985-03-13 1986-02-10 アラ−ガン・ハンフリ− 検眼装置
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
KR940000785B1 (ko) * 1986-04-02 1994-01-31 오오쓰까세이야꾸 가부시끼가이샤 카르보스티릴 유도체 및 그의 염의 제조 방법
DK167187A (da) * 1986-04-02 1987-10-03 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
JPH0696555B2 (ja) * 1986-07-31 1994-11-30 大塚製薬株式会社 カルボスチリル誘導体
DE3784401T2 (de) * 1986-07-31 1993-08-12 Otsuka Pharma Co Ltd Karbostyril-derivate und ihre salze, verfahren zu ihrer herstellung und diese enthaltende kardiotonische zusammensetzung.
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
EP0269383A3 (fr) * 1986-11-21 1990-05-02 A.H. Robins Company, Incorporated 1-Aryloxy-4-[(4-aryl)-1-pipérazinyl]-2-butanols utiles pour traiter des manifestations allergiques
FR2637591B1 (fr) * 1988-10-11 1992-10-23 Synthelabo Derives de quinoleinone, leur preparation et leur application en therapeutique
JP2608788B2 (ja) * 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2900130B2 (ja) * 1995-03-16 1999-06-02 大塚製薬株式会社 カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
MY138669A (en) * 2001-09-25 2009-07-31 Otsuka Pharma Co Ltd Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
WO2004043358A2 (fr) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Preparations d'agents bioactifs peu solubles et procedes pour les produire
SI1480953T2 (sl) * 2003-01-09 2010-12-31 Otsuka Pharma Co Ltd Postopek za pripravo aripiprazola
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
EP1644347A1 (fr) * 2003-06-20 2006-04-12 Arena Pharmaceuticals, Inc. Derives de n-phenyl-piperazine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5ht sb 2c /sb
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
ATE411797T2 (de) * 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2550726A1 (fr) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Procedes de preparation de formes cristallines d'aripiprazole
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
MXPA06008828A (es) * 2004-02-05 2007-04-25 Teva Pharma Proceso para preparar aripiprazol.
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP1812397A1 (fr) * 2004-11-18 2007-08-01 Synthon B.V. Procédé de synthèse d'aripiprazole cristallin
WO2006053780A1 (fr) * 2004-11-18 2006-05-26 Synthon B.V. Solvates cristallins d'aripiprazole
CA2594987A1 (fr) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Agent therapeutique pour la constipation
EP1844016A1 (fr) * 2005-01-27 2007-10-17 Sandoz AG Polymorph et solvates d'aripiprazole
EP1686126A1 (fr) * 2005-01-27 2006-08-02 Sandoz AG Sel d'aripiprazole
WO2006097344A1 (fr) * 2005-03-17 2006-09-21 Synthon B.V. Comprimes pharmaceutiques de forme cristalline d'aripiprazole ii
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
AR056321A1 (es) * 2005-04-22 2007-10-03 Wyeth Corp COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
CA2622758A1 (fr) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Formulations aripiprazoliques nanoparticulaires
EP1919453A2 (fr) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Procedes pour la reduction de la taille des particules d'aripiprazole
EP1988899A4 (fr) * 2006-02-03 2009-12-30 Reddys Lab Ltd Dr Co-cristaux d'aripiprazole
US20060223820A1 (en) * 2006-03-21 2006-10-05 Chemagis Ltd. Crystalline aripiprazole salts and processes for preparation and purification thereof
US7799790B2 (en) * 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
EP1880714A1 (fr) * 2006-07-20 2008-01-23 Helm AG Aripiprazole amorphe et son procédé de préparation
WO2008047340A1 (fr) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Thérapies combinées d'antipsychotiques et de tétracyclines dans le traitement de troubles psychiatriques
WO2008051541A2 (fr) * 2006-10-24 2008-05-02 Cambrex Charles City, Inc. Processus de préparation d'aripirazole anhydre de type i
ATE515554T1 (de) * 2006-12-04 2011-07-15 Merck Patent Gmbh Furochromanderivate
EP2162135A4 (fr) 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc Compositions, synthèses et procédés d'utilisation d'agents antipsychotiques atypiques à base de quinolinone
MY152789A (en) * 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
ES2353444T3 (es) 2008-01-23 2011-03-02 Helm Ag Aripiprazol amorfo y procedimiento para su preparación.
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
NZ589764A (en) * 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2009156889A1 (fr) * 2008-06-25 2009-12-30 Pfizer Inc. Composés diaryle et leurs utilisations
LT2445502T (lt) 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
MY162348A (en) 2009-09-11 2017-06-15 Otsuka Pharma Co Ltd Therapeutic agent for chronic pain
WO2011030213A1 (fr) 2009-09-14 2011-03-17 Jubilant Organosys Limited Procédé amélioré de préparation du 7-(4-bromobutoxy)-3,4-dihydrocarbostyrile, un précurseur de l'aripiprazole
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
EP3034079B1 (fr) 2010-11-15 2018-01-10 Agenebio, Inc. Dérivés de pyridazine, compositions et méthodes de traitement d'une déficience cognitive
BR112013023847B1 (pt) 2011-03-18 2021-02-23 Alkermes Pharma Ireland Limited composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
WO2012131451A1 (fr) 2011-03-30 2012-10-04 Jubilant Life Sciences Limited Procédé de production d'aripiprazole dans des cristaux anhydres de type i
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
AU2013235526B2 (en) 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
CA2867121C (fr) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Compositions pharmaceutiques comprenant des esters d'acides gras
JP6345651B2 (ja) * 2012-05-09 2018-06-20 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ヘテロアリール化合物及びその使用方法
KR101571670B1 (ko) 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
ES2652641T3 (es) * 2012-08-21 2018-02-05 Janssen Pharmaceutica Nv Haptenos de aripiprazol y su uso en inmunoensayos
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
EP3083569B1 (fr) 2013-12-20 2022-01-26 Agenebio, Inc. Dérivés de benzodiazépine, compositions et procédés de traitement de la déficience cognitive
CN106132415A (zh) 2014-03-20 2016-11-16 奥克梅斯制药爱尔兰有限公司 具有增加的注射速度的阿立哌唑制剂
KR20160139704A (ko) 2015-05-28 2016-12-07 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제, 및 이의 제조방법
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3761983A1 (fr) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Stratégie de dosage d'aripiprazole
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024039886A1 (fr) 2022-08-19 2024-02-22 Agenebio, Inc. Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
ES2963237A1 (es) * 2022-08-25 2024-03-25 Consejo Superior Investigacion Derivados de quinolina-2(1H)-ona para el tratamiento y prevención de enfermedades neurodegenerativas

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA801037A (en) * 1968-12-10 Regnier Gilbert Procede de preparation de nouveaux derives du piperazino-phenylethanol
GB1021522A (en) * 1963-05-10 1966-03-02 Ici Ltd 2-quinolone derivatives
GB1075156A (en) * 1963-08-27 1967-07-12 Luso Farmaco Inst Substituted piperazines
NL131192C (fr) * 1965-06-16
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US3703522A (en) * 1967-03-30 1972-11-21 Mcneilab Inc Carbostyril derivatives
US3706749A (en) * 1967-03-30 1972-12-19 Mcneilab Inc N-acyl carbostyrils
US3511841A (en) * 1967-05-29 1970-05-12 Sterling Drug Inc 1-((4-,5-,6-,and 7-azaindolyl)-lower-alkyl)- 4-substituted-piperazines
US3635976A (en) * 1967-12-20 1972-01-18 Pennwalt Corp 1 - heterocyclic alkyl-1 2 3 4-tetrahydroquinazolinones and analgesic intermediates thereof
CH514611A (de) * 1968-07-05 1971-10-31 Cassella Farbwerke Mainkur Ag Verfahren zur Herstellung von Derivaten des 2-Oxo-1,2-dihydro-chinolins
DE1795362A1 (de) * 1968-09-19 1972-01-05 Boehringer Mannheim Gmbh Basische AEther und Verfahren zur Herstellung derselben
BE884459Q (fr) * 1971-05-14 1981-01-26 Boehringer Mannheim Gmbh Derives de la 4-(omega-(coumarine-7-yl-oxy)-alkyl)-piperazine et procede de preparation
DE2123923A1 (de) * 1971-05-14 1972-11-23 Boehringer Mannheim Gmbh, 6800 Mannheim 4-eckige Klammer auf omega- (Flavon-7yl-oxy) -alkyl eckige Klammer zu -pigerazin-Derivate und Verfahren zu ihrer Herstellung
DE2335432A1 (de) * 1973-07-12 1975-01-30 Boehringer Mannheim Gmbh 3,4-dihydro-2h-naphthalinon-(1)5-oxy-propyl-piperazin-derivate und verfahren zu ihrer herstellung
US3910924A (en) * 1972-04-13 1975-10-07 Otsuka Pharma Co Ltd 3,4-Dihydrocarbostyril derivatives and a process for preparing the same
JPS517672B2 (fr) * 1972-04-13 1976-03-10
US4256890A (en) * 1972-09-14 1981-03-17 Otsukapharmaceutical Co., Ltd. 3,4-Dihydrocarbostyril derivatives and process for producing the same
DE2354145A1 (de) * 1972-11-02 1974-05-16 Sandoz Ag Chinazolin-2(lh)-one und verfahren zu ihrer herstellung
DE2334009A1 (de) * 1973-07-04 1975-01-23 Boehringer Mannheim Gmbh Purin-derivate sowie verfahren zu ihrer herstellung
US4026895A (en) * 1973-09-08 1977-05-31 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
US4117228A (en) * 1973-09-08 1978-09-26 Eisai Co., Ltd. 1,3-benzodioxol derivatives
US3981864A (en) * 1973-09-08 1976-09-21 Eisai Co., Ltd. 1,3-Benzodioxol derivatives
GB1451900A (en) * 1973-10-30 1976-10-06 Sandoz Ltd Quinolin-2-1h-ones
JPS5089376A (fr) * 1973-12-19 1975-07-17
US4032528A (en) * 1974-03-25 1977-06-28 Sandoz, Inc. 1,4-substituted-quinolin-2(1h)-ones as cns agents
US3983121A (en) * 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
US3940397A (en) * 1974-11-13 1976-02-24 E. R. Squibb & Sons, Inc. 2-[(Substituted-piperazinyl)alkyl]-1H-benz[de]isoquinoline-1,3(2H)-diones
DE2631317A1 (de) * 1975-07-23 1977-02-17 Sandoz Ag Organische verbindungen, ihre verwendung und herstellung
US3994900A (en) * 1976-01-23 1976-11-30 E. R. Squibb & Sons, Inc. 6-(Or 8)-[[(substituted amino)alkyl]oxy(or thio)]-3,4-dihydro-4-phenyl-2(1H)-quinolinones
ES456325A1 (es) * 1976-02-27 1978-05-01 Sandoz Ag Un procedimiento para la preparacion de nuevos derivados delacido 4-hidroxi-2-quinolinon-3-carboxilico.
US4210753A (en) * 1976-03-17 1980-07-01 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds
CH619453A5 (fr) * 1976-03-17 1980-09-30 Otsuka Pharma Co Ltd
DE2719562C2 (de) * 1976-05-08 1986-05-07 Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
US4110449A (en) * 1977-05-23 1978-08-29 E. R. Squibb & Sons, Inc. 2-substituted benzisothiazol-3-ones
US4166116A (en) * 1977-11-11 1979-08-28 Canadian Patents And Development Limited Pharmaceutical compositions containing piperazinyl acylhydroxamic acid derivatives to treat inflammation or anaphylactic allergy conditions
DE2960178D1 (en) * 1978-06-06 1981-04-09 Hoechst Ag New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
ES486992A1 (es) 1980-10-01
NO791049L (no) 1979-10-02
ES486991A1 (es) 1980-10-01
AU4548079A (en) 1979-10-04
NL183189C (nl) 1988-08-16
JPS6223750B2 (fr) 1987-05-25
SE7902794L (sv) 1979-10-01
CA1117110A (fr) 1982-01-26
GB2017701B (en) 1983-03-16
FI70704B (fi) 1986-06-26
GB2017701A (en) 1979-10-10
CH641350A5 (de) 1984-02-29
ES486990A1 (es) 1980-10-01
DK158225B (da) 1990-04-16
DE2912105C2 (de) 1985-08-29
NL7902514A (nl) 1979-10-02
AT376432B (de) 1984-11-26
CH641455A5 (de) 1984-02-29
MX5862E (es) 1984-08-13
AU515531B2 (en) 1981-04-09
DE2953723C2 (de) 1989-01-12
NO151321C (no) 1985-03-20
FR2421174B1 (fr) 1982-11-19
IT1119284B (it) 1986-03-10
US4734416A (en) 1988-03-29
SU1232144A3 (ru) 1986-05-15
NO151321B (no) 1984-12-10
ES479134A1 (es) 1980-06-16
ZA791516B (en) 1980-04-30
FI791034A7 (fi) 1979-10-01
ATA235179A (de) 1984-04-15
IT7967674A0 (it) 1979-03-30
SE434945B (sv) 1984-08-27
DE2912105A1 (de) 1979-10-11
DK158225C (da) 1990-09-17
DK128679A (da) 1979-10-26
JPS54130587A (en) 1979-10-09
PT69422A (en) 1979-04-01
BE875174A (fr) 1979-10-01
FR2421174A1 (fr) 1979-10-26
SU1140687A3 (ru) 1985-02-15
US4824840A (en) 1989-04-25

Similar Documents

Publication Publication Date Title
FI70704C (fi) Foerfarande foer framstaellning av ett karbostyrilderivat med antihistamineffekt och inverkan pao centrala nervsystemet
DE69130412T2 (de) Pyrazolopyridinverbindung und Verfahren zu ihrer Herstellung
WO2000006550A1 (fr) Composes phenylazole, procede de production desdits composes et medicaments pour le traitement de l'hyperlipidemie
KR970011298B1 (ko) 벤즈이미다졸류로부터 유도된 무진정성 항히스타민제
RO113242B1 (ro) Derivati de indol, procedee de preparare, compozitie farmaceutica si metoda de tratament
JPH0587077B2 (fr)
AU2001239331A1 (en) Derivatives of quinoline as alpha-2 antagonists
NZ514814A (en) Quinoline derivatives as inhibitors of MEK enzymes
FI76322C (fi) Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara karbostyrilderivat.
HU215125B (hu) Eljárás 3-[aril-(tio)karbonil]-1-amino-alkil-1H-indol-származékokat tartalmazó, glaukóma-elleni gyógyszerkészítmények előállítására
EP1037887B1 (fr) 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique
EP0577325A1 (fr) Dérivés de carbostyriles et agent anti-allergique
KR910009934B1 (ko) 카르바모일-2-피롤리디논 화합물
WO1989005803A1 (fr) Derives de 3,4-dihydro-2h-1,3-benzoxazine et leur utilisation en medecine
RU2138501C1 (ru) Имидазопиридиназолидиноны, их соли и лекарственное средство
KR930009355B1 (ko) 피리도[1, 2-a]피리미딘 유도체의 제조법
JPS6377856A (ja) 新規なフェニル、ピロリジン―２―イル置換５員複素環化合物およびその製造方法並びにこの化合物を有効成分とする抗精神病医薬組成物
WO2008135578A1 (fr) Dérivés de pyrazolo [3,4-d] pyrimidine pour le traitement de l'inflammation et/ou des états allergiques
EP2970210B1 (fr) Dérivés de pyrazolylbenzo[d]imidazole
EP0204003A1 (fr) Derives de 2-(1-piperazinyle)-4-substitue phenylquinoline, procede de preparation et composition medicinale les contenant
US6593324B2 (en) Dervatives of quinoline as alpha-2 antagonists
JPS6331445B2 (fr)
KR820002231B1 (ko) 신규 카르보스티릴 유도체의 제조방법
EP0686630B1 (fr) Dérivés de quinoléine et compositions pharmaceutiques les contenant
JPS63119467A (ja) カルボスチリル誘導体

Legal Events

Date Code Title Description
MA Patent expired
MA Patent expired

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.